JNJ vs REGN
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. REGN: Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases.
Side-by-side fundamentals
| Metric | JNJ | REGN | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $273.04 | $828.50 | |
| Market cap as of 2026-08-24 | $658.0B | $77.8B | |
| P/E as of 2026-08-24 | 31.66 | 20.48 | REGN lower |
| PEG as of 2026-08-24 | 3.39 | 1.08 | REGN lower |
| Net margin as of 2026-08-24 | +21.5% | +27.9% | REGN higher |
| Gross margin as of 2026-08-24 | +68.0% | +86.0% | REGN higher |
| Operating margin as of 2026-08-24 | +25.7% | +24.7% | JNJ higher |
| ROE as of 2026-08-24 | +25.7% | +13.8% | JNJ higher |
| ROA as of 2026-08-24 | +10.6% | +10.6% | Tie |
| Debt / equity as of 2026-08-24 | 0.58 | 0.09 | REGN lower |
| Revenue growth (YoY) as of 2026-08-24 | +8.1% | +9.3% | REGN higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | +5.6% | JNJ higher |
| Dividend yield as of 2026-08-24 | +3.1% | +0.5% | JNJ higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-24 | -0.02 | 0.62 | |
| 1-year return as of 2026-08-24 close | +52.3% | +40.5% | JNJ higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.